Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Irritable Bowl Syndrome Linked to Chili Pepper Pain Receptor

By Labmedica staff writers
Posted on 18 Jun 2008
Scientists have discovered that people with irritable bowl syndrome (IBS) have higher than usual levels of nerve fibers expressing the transient receptor potential vanilloid 1 (TRPV1), responsible for causing a burning sensation when people eat chili peppers. More...
TRPV1 receptors are also known as capsaicin receptors.

A study, which was published in the June 11, 2008, issue of the journal Gut, suggests that doctors will be able to treat the pain suffered by people with IBS by targeting and blocking the pain receptor. People with severe pain from IBS are currently treated with opiates, which can have serious side effects. Painkillers such as paracetamol and ibuprofen tend to offer little relief. New painkillers to target TRPV1 are currently being developed by pharmaceutic companies and the new findings suggest that such drugs could tackle some of the symptoms of IBS.

Biopsies were studied of colon tissue taken from 23 patients with IBS and from 22 controls, recruited from the gastroenterology clinics and the endoscopy department at Imperial College Healthcare National Health Service (NHS) Trust (London, UK). An estimated one in five UK adults have irritable bowel syndrome (IBS), a painful condition that is poorly understood. Symptoms of IBS include abdominal pain, bloating, and bowel problems such as constipation or diarrhea.
The investigators believe their findings may explain why some people's IBS symptoms worsen after eating spicy food. They also suggest that the presence of more nerve fibers expressing the TRPV1 pain receptors might mean that people with IBS are more susceptible to pain. TRPV1 receptors are also known as capsaicin receptors.


Related Links:
Imperial College Healthcare National Health Service Trust

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.